Nobivac® Canine 1-DAPPv+L4

Canine Distemper, Adenovirus Type 2, Parainfluenza, Parvovirus Vaccine, MODIFIED LIVE VIRUS, Leptospira Canicola- Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterin

A multi-purpose 1-year vaccine that has 2 critical indications in the protection against leptospirosis and also protects against all strains of canine parvovirus (CPV).

Features and benefits

  • Protects against all known strains of CPV, including CPV-2c1-3
    • Contains CPV-2b, one of the most prevalent field strains of parvovirus
    • High antigenic mass (titer), low passage parvovirus vaccine
    • Overrides maternal antibodies in young puppies4
  • The only leptospirosis vaccine to protect and defend against mortality and urinary shedding
  • Prevented mortality caused by 4 virulent Leptospira serovars4
  • Protects against 2 types of adenovirus that cause hepatitis and respiratory disease in dogs
  • Provides disease coverage for commonly spread canine viruses, distemper, and parainfluenza, in 1 formula


  • Approved for the vaccination of healthy dogs as an aid in the prevention of disease caused by canine distemper virus, adenovirus types 1 and 2, parainfluenza, and parvovirus
  • Indicated as an aid in the prevention of disease and mortality caused by L. canicola, L. icterohaemorrhagiae, L. pomona, or L. grippotyphosa
  • Prevents leptospiruria associated with L. grippotyphosa, L. canicola, or L. icterohaemorrhagiae
  • Aids in the prevention of leptospiruria associated with L. pomona
  • Recommended for use in healthy dogs 8 weeks of age or older

Safety information

  • Safety confirmed in 749-dog field study4
  • Proven safe across a variety of dog breeds and ages
  • Now featuring an even higher level of quality due to new VacciPure™ filtration

Please see the product label for additional safety information.

Administration and Dosage

  • Subcutaneous injection
  • Two 1-mL doses given 2 to 4 weeks apart
  • Last dose may be given at 12 weeks of age
  • Annual revaccination with 1 dose is recommended
  • Available in a 25 x 1-mL dose

For further information, including complete directions and warnings, please see the product label.

Product label(s) and MSDS


  1. Larson LJ, Schultz RD. Do two current canine parvovirus type 2 and 2b vaccines provide protection against the new type 2c variant? Vet Ther. 2008;9(2):94–101.
  2. Schultz RD, Thiel B, Mukhtar E, Sharp P, Larson LJ. Age and long-term protective immunity in dogs and cats. J Comp Pathol. 2010;142 Suppl 1:S102–S108.
  3. Spibey N, Greenwood NM, Sutton D, Chalmers WS, Tarpey I. Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus. Vet Microbiol. 2008;128(1–2):48–55.
  4. Data on file, Merck Animal Health.